Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Vitamin D Supplements and Risk of Type 2 Diabetes
Clinical Breakthroughs

Vitamin D Supplements and Risk of Type 2 Diabetes

By Anna WilliamsJul 8, 2019
Share
Facebook Twitter Email
Lisa Neff, MD, assistant professor of Medicine in the Division of Endocrinology, Metabolism and Molecular Medicine, was a co-author of the study published in The New England Journal of Medicine.

Daily vitamin D supplements did not significantly reduce the risk of Type 2 diabetes among adults at high risk for the disease, according to the results of a large clinical trial published in The New England Journal of Medicine.

Lisa Neff, MD, assistant professor of Medicine in the Division of Endocrinology, Metabolism and Molecular Medicine, was a co-author of the study.

Previous research had suggested a link between low blood levels of vitamin D and the risk of developing Type 2 diabetes, and small studies had further demonstrated improved pancreatic beta-cell function with vitamin D supplementation. However, it was unclear whether vitamin D supplements could in fact lower the risk of diabetes among patients.

The current study, the Vitamin D and Type 2 Diabetes (D2d) trial, was the largest to examine whether daily vitamin D supplementation helps prevent diabetes among people who are at high risk.

In the study, investigators at 22 academic medical centers across the U.S. randomly assigned 2,423 adults with prediabetes to receive either a daily supplement of 4,000 units of vitamin D3 or a placebo. The participants were screened for diabetes with blood tests every six months.

After a median follow-up of 2.5 years, the study found that slightly fewer participants in the vitamin D group (24.2 percent) developed diabetes than in the placebo group (26.7 percent), but this difference was not statistically significant.

The authors note that study participants were not selected for vitamin D insufficiency, and at the time of enrollment about 80 percent had vitamin D levels considered adequate; this may have limited the study’s ability to detect a benefit of supplementation.

“Future studies should evaluate whether vitamin D supplementation reduces the risk of diabetes in individuals with prediabetes and very low levels of vitamin D,” Neff said.

Neff and her collaborators are also digging deeper into the results of the current trial.  “We are continuing to analyze data collected in this study and plan to address other important questions about risk factors for diabetes and the role of vitamin D in health,” she said.

The planning phase of the D2d trial was funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) through a multicenter clinical study implementation planning grant to Tufts Medical Center in Boston (U34DK091958). Planning was also supported, in part, by the Intramural Research Program of the NIDDK. The conduct of the trial was supported primarily by the NIDDK and the Office of Dietary Supplements of the National Institutes of Health through the multicenter clinical study cooperative agreement (U01DK09824) to Tufts Medical Center, where the D2d Coordinating Center is based. The trial also received secondary funding from the American Diabetes Association to Tufts Medical Center (1-14-D2d-01). Educational materials were provided by the National Diabetes Education Program.

Health and Lifestyle Public Health Research
Share. Facebook Twitter Email

Related Posts

Self-Powered Wireless Implant Delivers Medication, Then Dissolves

Mar 30, 2023
Mar 29, 2023

Adolescent Sexual Health Program Receives Funding for Social Marketing Campaign

Mar 29, 2023

The Future of IgE-Mediated Allergy Research and Treatments

Mar 29, 2023

Comments are closed.

Latest News

NUDOCS Program Inspires the Next Generation of Physicians

Mar 31, 2023

Women in Medicine Conference Celebrates Community

Mar 31, 2023

Self-Powered Wireless Implant Delivers Medication, Then Dissolves

Mar 30, 2023

Adolescent Sexual Health Program Receives Funding for Social Marketing Campaign

Mar 29, 2023

The Future of IgE-Mediated Allergy Research and Treatments

Mar 29, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20230317_NM651
20230317_NM610
20230317_NM569
20230317_NM537
20230317_NM331
20230317_NM323
20230317_NM316
20230317_NM336
20230317_NM626
20230317_NM662
20230317_NM655
20230317_NM642

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.